## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

Liora CAHALON et al

Serial No.:

10/002,145

Filed:

December 5, 2001

For:

**NOVEL ANTI-CANCER THERAPEUTIC** 

**COMPOUNDS** 

Examiner:

HUI, SAN MING R

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 JUL 2 1 2006 W

Group Art Unit: 1617

Attorney

Docket: 24214



Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Supplemental Information Disclosure Statement is being filed subsequent to an Office Action being mailed and a late fee of \$180 is due. Please charge my Deposit Account 50-1407 for this fee, as well as any additional fees due.

This Supplemental Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

07/25/2006 HALI11

00000032 501407 10002145

01 FC:1806

180.00 DA

Respectfully submitted,

Martin D. Mopula

Martin D. Moynihan

Registration No. 40,338

Dated: July 18, 2006

JUL 2 1 2006

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are require PADEMAR

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Sheet

Complete if Known			
Application Number	10/002,145		
Filing Date	December 5, 2001		
First Named Inventor	Liora CAHALON et al		
Art Unit	1617		
Examiner Name	HUI, SAN MING R		

24214

Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where	
Initials*	No. <sup>1</sup>	Number-Kind Code <sup>2 (if known)</sup>	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
	1	US-5,474,987	12-12-1995	Cohen et al.		
	2	US-5,686,431	11-11-1997	Cohen et al.		
	3	US-5,908,837	01-1-1999	Cohen et al.		
	4	US-4,468,385	08-28-1984	Callahan et al.		
	5	US-5,580,858	03-3-1996	Ippolito et al.		
	6	US-1,950,100	06-6-1934	Lathan A. Crandall		
•						

Attorney Docket Number

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. 1	Foreign Patent Documents  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	7	PCT WO 89/05645	06-29-1989	Bar-Shalom et al.		
				·		Ш
				<u> </u>		Ш
	ļ		ļ			Ш
<u> </u>	<u> </u>		<u></u>	<u> </u>		ᆚᆚ
Examine Signatur				Date Considered		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

## PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE equired to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwo		CMABERS	Comple	ete if Known		
Substitute for form-1449A/PTO			Application Number 10/002,145			
				December 5, 2001		
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date First Named Inventor				
			Liora CAHALON et al			
		Group Art Unit	HUI, SAN MING R			
		Examiner Name				
	(use a	as many sheets as necessary)				
Sheet	2	Of 2	Attorney Docket Number	24214		
		OTHER PRIOR ART – NON PATE	NT LITERATURE DOCUM	1ENTS		
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS item (book, magazine, journal, serial symposium, ca publisher, city and/or co	atalog, etc.) date, page(s), volume-issue number(s),			
	8	Riley et al " A Comparison of Sucralfate and Prednisolone Enemas in the Treatment of Active Distal Ulcerative Colitis", The Scandinavian Journal of Gastroenterology, 24(8): 1014-1018, 1989.				
	9	Basic & Clinical Immunology "Autoimmunity", Pulished by Lange Medical Publications in 1984, edited by Daniel P.Sites et al; chapter 12, pp. 152-186				
	10	The Merck Manuel "The Merck Manuel of Diagnosis and Therapy", 17th Ed., P.426-430, 872-875, 1999.				
	11	Venkataraman et al. "Sequencing Complex 1999.	Polysaccharides", Science, 2	286: 537-542,		

Signature	Considered	

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional).

2. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.